|
1
|
Chayama K, Hayes CN, Ohishi W and Kawakami
Y: Treatment of chronic hepatitis C virus infection in Japan:
update on therapy and guidelines. J Gastroenterol. 48:1–12. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim MN, Kim BK and Han KH: Hepatocellular
carcinoma in patients with chronic hepatitis C virus infection in
the Asia-Pacific region. J Gastroenterol. 48:681–688. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chuang WL and Yu ML: Host factors
determining the efficacy of hepatitis C treatment. J Gastroenterol.
48:22–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Minami T, Kishikawa T, Sato M, Tateishi R,
Yoshida H and Koike K: Meta-analysis: mortality and serious adverse
events of peginterferon plus ribavirin therapy for chronic
hepatitis C. J Gastroenterol. 48:254–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamashita N, Ohho A, Yamasaki A, Kurokawa
M, Kotoh K and Kajiwara E: Hepatocarcinogenesis in chronic
hepatitis C patients achieving a sustained virological response to
interferon: significance of lifelong periodic cancer screening for
improving outcomes. J Gastroenterol. 49:1504–1513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishiguchi S, Enomoto H, Aizawa N, et al:
Relevance of the Core 70 and IL-28B polymorphism and
response-guided therapy of peginterferon alfa-2a ± ribavirin for
chronic hepatitis C of Genotype 1b: a multicenter randomized trial,
ReGIT-J study. J Gastroenterol. 49:492–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asahina Y, Tsuchiya K, Nishimura T, et al:
Genetic variation near interleukin 28B and the risk of
hepatocellular carcinoma in patients with chronic hepatitis C. J
Gastroenterol. 49:1152–1162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyase S, Haraoka K, Ouchida Y, Morishita
Y and Fujiyama S: Randomized trial of peginterferon alpha-2a plus
ribavirin versus peginterferon alpha-2b plus ribavirin for chronic
hepatitis C in Japanese patients. J Gastroenterol. 47:1014–1021.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Enomoto M, Tamori A, Kobayashi S, Iwai S,
Morikawa H and Kawada N: Treatment guidelines for HCV genotype 1:
mono for low, triple for high, and dual for ‘middle’? J
Gastroenterol. 48:555–556. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sato M, Kato N, Tateishi R, et al: I128B
minor allele is associated with a younger age of onset of
hepatocellular carcinoma in patients with chronic hepatitis C virus
infection. J Gastroenterol. 49:748–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okita K, Izumi N, Matsui O, et al:
Peretinoin after curative therapy of hepatitis C-related
hepatocellular carcinoma: a randomized double-blind
placebo-controlled study. J Gastroenterol. Apr 13–2014.(Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Izumi N, Asahina Y, Kurosaki M, et al:
Inhibition of hepatocellular carcinoma by PegIFN α −2a in patients
with chronic hepatitis C: a nationwide multicenter cooperative
study. J Gastroenterol. 48:382–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fried MW, Shiffman ML, Reddy KR, et al:
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection. N Engl J Med. 347:975–982. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kurosaki M, Tanaka Y, Nishida N, et al:
Pre-treatment prediction of response to pegylated-interferon plus
ribavirin for chronic hepatitis C using genetic polymorphism in
I128B and viral factors. J Hepatol. 54:439–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hézode C, Forestier N, Dusheiko G, et al:
Telaprevir and peginterferon with or without ribavirin for chronic
HCV infection. N Engl J Med. 360:1839–1850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Izumi N, Hayashi N, Kumada H, et al:
Once-daily simeprevir with peginterferon and ribavirin for
treatment-experienced HCV genotype 1-infected patients in Japan:
the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 49:941–953.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Liu F, Wei F, Ren H and Hu H:
Efficacy and safety of pegylated interferon plus ribavirin therapy
for chronic hepatitis C genotype 6: a meta-analysis. PLoS One.
9:e1001282014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holder KA, Stapleton SN, Gallant ME,
Russell RS and Grant MD: Hepatitis C virus-infected cells
downregulate NKp30 and inhibit ex vivo NK cell functions. J
Immunol. 191:3308–3318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonzalez VD, Falconer K, Björkström NK, et
al: Expansion of functionally skewed CD56-negative NK cells in
chronic hepatitis C virus infection: correlation with outcome of
pegylated IFN-alpha and ribavirin treatment. J Immunol.
183:6612–6618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeromski J, Mozer-Lisewska I, Kaczmarek M,
Kowala-Piaskowska A and Sikora J: NK cells prevalence, subsets and
function in viral hepatitis C. Arch Immunol Ther Exp (Warsz).
59:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jinushi M, Takehara T, Tatsumi T, et al:
Impairment of natural killer cell and dendritic cell functions by
the soluble form of MHC class I-related chain A in advanced human
hepatocellular carcinomas. J Hepatol. 43:1013–1020. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jinushi M, Takehara T, Kanto T, et al:
Critical role of MHC class I-related chain A and B expression on
IFN-alpha-stimulated dendritic cells in NK cell activation:
impairment in chronic hepatitis C virus infection. J Immunol.
170:1249–1256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iino S, Ichida F, Sakuma A and Suzuki H: A
randomized clinical trial with natural interferon-alpha monotherapy
for 24 or 48 weeks on patients with chronic hepatitis C having
genotype 1b infection in high viral titers. Hepatol Res.
24:338–345. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Enomoto N, Sakuma I, Asahina Y, et al:
Mutations in the nonstructural protein 5A gene and response to
interferon in patients with chronic hepatitis C virus 1b infection.
N Engl J Med. 334:77–81. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akuta N, Suzuki F, Kawamura Y, et al:
Predictors of viral kinetics to peginterferon plus ribavirin
combination therapy in Japanese patients infected with hepatitis C
virus genotype 1b. J Med Virol. 79:1686–1695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yasui K, Harano Y, Mitsuyoshi H, et al:
Steatosis and hepatic expression of genes regulating lipid
metabolism in Japanese patients infected with hepatitis C virus. J
Gastroenterol. 45:95–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Izumi N, Asahina Y and Kurosaki M:
Predictors of virological response to a combination therapy with
pegylated interferon plus ribavirin including virus and host
factors. Hepat Res Treat. 2010:7036022010.PubMed/NCBI
|
|
28
|
Tanaka Y, Nishida N, Sugiyama M, et al:
Genome-wide association of I128B with response to pegylated
interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat
Genet. 41:1105–1109. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ge D, Fellay J, Thompson AJ, et al:
Genetic variation in I128B predicts hepatitis C treatment-induced
viral clearance. Nature. 461:399–401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kobayashi M, Suzuki F, Akuta N, et al:
Association of two polymorphisms of the I128B gene with viral
factors and treatment response in 1,518 patients infected with
hepatitis C virus. J Gastroenterol. 47:596–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahlenstiel G, Booth DR and George J:
IL-28B in hepatitis C virus infection: translating pharmacogenomics
into clinical practice. J Gastroenterol. 45:903–910. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ichida F, Tsuji T, Omata M, et al: New
Inuyama classification; new criteria for histological assessment of
chronic hepatitis. Int Hepatol Commun. 6:112–119. 1996. View Article : Google Scholar
|
|
33
|
Ochi H, Maekawa T, Abe H, et al: IL-28B
predicts response to chronic hepatitis C therapy - fine-mapping and
replication study in Asian populations. J Gen Virol. 92:1071–1081.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kurosaki M, Sakamoto N, Iwasaki M, et al:
Pretreatment prediction of response to peginterferon plus ribavirin
therapy in genotype 1 chronic hepatitis C using data mining
analysis. J Gastroenterol. 46:401–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sinn DH, Kim YJ, Lee ST, et al:
Association of a single nucleotide polymorphism near the
interleukin-28B gene with response to hepatitis C therapy in Asian
patients. J Gastroenterol Hepatol. 26:1374–1379. 2011.PubMed/NCBI
|
|
36
|
Cox ST, Madrigal JA and Saudemont A:
Diversity and characterization of polymorphic 5′ promoter
haplotypes of MICA and MICB genes. Tissue Antigens. 84:293–303.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kimura T, Goto K, Yabuki K, et al:
Microsatellite polymorphism within the MICB gene among Japanese
patients with Behçet's disease. Hum Immunol. 59:500–502. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodriguez-Rodero S, Rodrigo L, Fdez-Morera
JL, et al: MHC class I chain-related gene B promoter polymorphisms
and celiac disease. Hum Immunol. 67:208–214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
González SI, Rodrigo L, López-Vázquez A,
et al: Association of MHC class I related gene B (MICB) to celiac
disease. Am J Gastroenterol. 99:676–680. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan F, Li L, Luo J, Liu X and Tian W: The
5′ promoter region of MHC class I chain-related gene B. Tissue
Antigens. 83:337–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
